Over the next decade the number of patients reaching end stage renal disease (ESRD) will double as a result of the progression of chronic diseases of the kidney (CKD)([@R1]) but the rate of progression is difficult to predict using serum creatinine (sCr) or proteinuria measurements alone. sCr is confounded by age, muscle mass, gender, race, medications, hydration status and extrarenal clearance ([@R2]), and progression may occur even in the absence of proteinuria ([@R3]). Tubulo-interstitial disease perhaps best presages worsening CKD ([@R3]), however, kidney biopsy is not practical for routine use and generally does not sample medullary tubules. Here, we evaluated relationships between a urinary protein and biopsy findings in a CKD cohort.

Neutrophil Gelatinase Associated Lipocalin (NGAL) gene product ("monomeric" Lcn2, Siderocalin 23--26KDa protein ([@R4])) is induced by the triggers of acute kidney injury (AKI)([@R4]--[@R6]). NGAL is also induced by actively progressive CKD ([@R7]), advancing HIVAN ([@R8]), and end stage ([@R9]) in the absence of an acute event. It is important to correlate the specific molecular form of NGAL with kidney histology, not only to determine whether it serves as a reporter, but also to determine whether a specific form might participate in the growth of damaged tubules ([@R9]) or the defense of the urinary tract by scavenging iron ([@R10]).

To determine the molecular form of NGAL, we analyzed the urine of 99 patients by immunoblot and found a recurrent pattern of immunoreactivities. The majority of NGAL was "monomeric", but additional reactivities were found at \>250, 125, 75KDa in non-reducing gels. The 75KDa species was potentially trimeric NGAL, and the 125KDa species was potentially NGAL-MMP-9 ([@R11]) but the \>250KDa immunoreactive band was a novel complex. To identify this protein, we fractionated the urine of a Stage 5 patient using cation-exchange and gel filtration. Mass methodology identified the \>250KDa complex as the secretory component of the polymeric immunoglobulin receptor (peptides: LVSLTLNLVTR; ILLNPQDKDGSFSVVITGLR; QGHFYGETAAVYVAVEER) together with α2-macroglobulin. Upon reduction, monomeric NGAL dissociated from the complex ([Figure 1](#F1){ref-type="fig"}).

Because the monomeric form of NGAL has been specifically associated with epithelial stress ([@R4], [@R5]), we decided to quantify this species with ARCHITECT-NGAL (Abbott) assays ([@R6]) which correlated with immunoblot detection of the monomer (r =0.69, p\<0.001), demonstrating the same rank order, and producing nearly identical statistical differences (ANOVA) across different diagnoses (\<0.05, ARCHITECT-NGAL and \<0.01, immunoblot). The ARCHITECT-NGAL demonstrated that 3.8% (SD 7.7%) of the immunoreactivity was \>100KDa, but with variable contribution (0--41.9%).

Accurate quantification of the monomer permitted a comparison with clinical and pathological characteristics in the concurrent biopsy ([Supplemental Table 1](#SD1){ref-type="supplementary-material"}). Rapidly progressive glomerulonephritis (n=3), dialysis (n=10), and AKI were excluded at the time of enrollment. Six percent of our cohort had been on steroids prior to biopsy. On average, the cohort was male (70%), age 52.2 years (SD 16.8) with a GFR 57.7 mL/min (SD 34.5); hypertension was common (69.7%, mean 138.7 mmHg SD 22.0 / 81.9 mmHg SD 11.3) but diabetes was present in only 18.2%. Pathological diagnoses were diverse: Nephrotic syndromes (49.5%: membranous, focal segmental glomerulosclerosis, minimal change disease and amyloidosis), nephritic syndromes (31%: IgA and lupus nephropathies, membranoproliferative and mesangial proliferative glomerulonephridites, fibrillary and immunotactoid nephritis), diabetic nephropathy (10%), and other diagnoses (9%: nephroangiosclerosis, ESRD prior to dialysis initiation, light chain nephritis, myeloma, and isolated chronic tubulo-interstitial nephritis).

While the monomer appeared most elevated in diabetics ([Supplemental Table 1](#SD1){ref-type="supplementary-material"}), statistical significance was demonstrated by measures of disease chronicity rather than specific diagnoses. For example, the monomer correlated inversely with GFR (r=−0.53, p\<0.001) and directly with chronicity indices (p=0.003) in a dose-responsive relationship ([Figure 2](#F2){ref-type="fig"}). Additionally, the monomer specifically associated with both tubular atrophy (p=0.002) and interstitial fibrosis (p=0.006). Moderate or severe fibrosis or atrophy were associated with 3--4 fold higher levels of NGAL monomer (each p\<0.01) compared to mild or absent fibrosis or atrophy ([Table1](#T1){ref-type="table"}, [Figure 3](#F3){ref-type="fig"}). Similarly, fibrous crescents (p=0.001) and global glomerulosclerosis (p=0.037) were highly correlated with the monomer, both suggestive of chronic damage. For example, 96% of patients with fibrous crescents had some degree of TI disease, 35% moderate or severe. 99% of patients with global glomerulosclerosis demonstrated tubulointerstitial disease, 44% of which had moderate or severe levels. Diabetics may have somewhat higher levels of NGAL because 75% demonstrated moderate to severe interstitial fibrosis (vs. nephrotic syndrome (26%), p=0.002; vs. nephritic syndrome (9%), p=0.002) and tubular atrophy (vs. nephrotic syndrome (28%), p=0.001; vs. nephritic syndrome (16%), p=0.002) in excess of other forms of CKD, but without significant differences in GFR. The monomer also associated with proteinuria (r=0.27, p=0.008), albeit the association weakened upon adjustment for GFR (r=0.20, p=0.06).

In contrast, the monomer was not associated with activity indices of glomerular disease (p=0.847, [Figure 2](#F2){ref-type="fig"}) including glomerular leukocyte infiltrates (p=0.34), mesangial proliferation (p=0.616), cellular crescents (p=0.569), fibrinoid necrosis (p=0.168), nor strongly with monocellular-predominant interstitial infiltrates (p=0.056), while there was an association with mesangial matrix expansion (p=0.004) implying that the monomer was better associated with chronic rather than acute cellular changes.

Neutrophils and macrophages may be present in the interstitium and contribute to NGAL but our pathological analysis failed to associate monomer with interstitial cellular infiltrates including the dominant lympho-monocytic interstitial infiltrate. Additionally, iso-electric point analysis of DTT reduced samples demonstrated similar iso-electric points for monomeric NGAL in patients with AKI or CKD (pI 7.1, 8.2, 8.5, 8.8--9.2), whereas neutrophil NGAL demonstrated a different pattern of alkaline shifted species (pI 8.5--9.2). Urinary myeloperoxidase, a protein released from neutrophils, also did not correlate with NGAL monomer in the current (R^2^=0.087) or in a previously identified cohort (R^2^=0.0092) whereas NGAL and myeloperoxidase were highly correlated in isolated blood neutrophils (R^2^=0.99).

In summary, while the monomer of NGAL was the predominant, if not the only form expressed in AKI, known and novel complexes formed by disulfide linkages were found in CKD urine. These complexes might form in Thick Ascending Limb or in the urinary space because both the extracellular secretory component of polymeric IgR (68KDa) and NGAL are secreted from the luminal membrane of the TAL ([@R12]). α-2-macroglobulin can also be found in CKD urine ([@R13]) whereas its receptor LRP1/CD91 is found in the tubulo-interstitial compartment where it may concentrate and endocytose α2-macroglobulin ([@R14]). Perhaps these transport proteins provide a clearance mechanism, rather than directly depict epithelial damage. In this light, the site of complex formation might clarify their clinical significance, as recently demonstrated by the localization of dimer to neutrophils, and monomer to epithelia ([@R15]).

Most importantly, this study showed that monomer reflects the severity of tubulo-interstitial, rather than glomerular specific pathologies ([@R3]). Tubulointerstitial genes (Scara5, Col6a~1-3~, Nfix, Acvrl1, and myogenic proteins; Yang, Schmidt-Ott, Barasch, Unpublished) induced by NGAL in rat kidney mesenchyme are compatible with this hypothesis. These data are novel because they suggest that the monomer is expressed in many common forms of advanced CKD, whereas previously characterized patterns of NGAL expression were disease restricted such as the HIVAN microcyst ([@R8]) and the TAL and α-intercalated cell in AKI ([@R5]). Consequently, we propose that the association of NGAL with kidney disease may be better appreciated by specific measurements of monomer, since NGAL complexes \>100KDa contribute variably to total immunoreactivity and potentially involve proteins from non-renal cell types. The same type of molecular analysis applies to other urinary 'biomarkers' as well.

METHODS {#S1}
=======

The University of Parma and Columbia approved the study; informed consent was obtained. Patients (1/2005 -- 4/2008) were \>18 yrs. Urine was centrifuged (12,000rpm × 10min), stored (between 2 months-3 years at −80°C) and analyzed in batch with non-reducing 4% to 15% polyacrylamide gels (Bio-Rad Laboratories, Hercules, CA) and monoclonals (1:1000; AntibodyShop, Gentofte, Denmark) using standards (0.3 to 3ng) of human NGAL by workers blinded to biopsy data. ARCHITECT-NGAL assays were performed at Cincinnati Children's Hospital. Immunoreactivity was evaluated by filtering the urine (Microcon Ultracel YM-100, 100kDa filter; Millipore Corporation), or by MiniS (Mes 20mM, pH6.0 + gradient of NaCl, 0.5M) and Superdex200 (PBS) chromatography. NGAL containing complexes were digested with trypsin, batch fractionated on a Poros 50 R2 RP micro-tip, and the resulting peptide pools analyzed by MALDI-reTOF, using a BRUKER UltraFlex TOF/TOF instrument (Bruker Daltonics; Bremen, Germany) ([@R16]). Selected experimental masses (m/z) were taken to search human non-redundant protein database (NCBI) utilizing the Mascot Peptide Mass Fingerprint ([@R17]), version 2.3.01, with a mass accuracy restriction better than 35 ppm, and maximum allowed one cleavage site missed per peptide. To confirm PMF results with scores \<40, mass spectrometric sequencing of selected peptides was done by MALDI-TOF/TOF (MS/MS) re-analysis, using the UltraFlex instrument in 'LIFT' mode. Fragment ion spectra were taken to search NR using Mascot MS/MS Ion Search program ([@R17]). Iso-electric focusing (Kendrick Labs, Madison, WI; ([@R18]) utilized PVDF immunoblotting.

Kidney biopsies (obtained as part of routine care in all subjects at the time of urine sampling) were formalin-fixed, paraffin embedded, and sections stained with hematoxylin/eosin, Masson's trichrome stain, silver methenamine and periodic-acid Schiff. IgG, IgM, IgA, C3 and fibrinogen deposition were detected by immunoflourescence. Biopsies were graded by two independent pathologists blinded to both diagnosis and NGAL level. Glomerular, tubular, interstitial and vascular lesions were scored as 0, absent; 1, mild; 2, moderate; 3, severe.

The sensitivity of myeloperoxidase ELISA (Alpco. Co) was determined using serial dilutions of neutrophils isolated from citrated blood ([@R19]). While the ELISA was sensitive to a 0.01X dilution, immunoblot detection of NGAL was consistent only to 0.1X, indicating that detection of myeloperoxidase compared favorably with NGAL. GFR was estimated by MDRD formula ([@R20]), uCr measured by QuantiChrom Creatinine Assay Kit (BioAssay Systems), sCr by Jaffe, uProtein by nephelometry.

Statistical analysis (SPSS v16.0, Chicago) {#S2}
------------------------------------------

Continuous variables were log-transformed and compared by Student's t-test for unequal variances or ANOVA. Categorical variables were compared by χ^2^. The null hypothesis was rejected at p\<0.05. Data were represented as the mean ± standard deviation (SD).

Supplementary Material {#S6}
======================

###### Supplemental Table 1

Mean values and cohort baseline characteristics by etiology of CKD, including urinary NGAL monomer.
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![Urine was fractionated by cation exchange chromatography and fractions containing immunoreactive NGAL species were then separated by filtration chromatography (Left Panels). Note that the monomer (23--26KDa, fractions 24--32) comprised the majority of immunoreactive NGAL, but additional species can be found at 75KD (fractions 19--23), 125KDa (fractions 15--18) and \>250KDa (fractions 9--11). When the latter were pooled and reduced, the only immunoreactive species was the monomer (Right). These data show that in advanced CKD, a proportion of NGAL is associated with other proteins.](nihms373055f1){#F1}

![Urinary NGAL (uNGAL) monomer according to (A) chronicity and (B) activity indices of kidney biopsies concurrent with the urine samples. \* P\<0.01 compared to scores 8--11 in panel A. Scatter plot of uNGAL monomer according to GFR (C), r=−0.53, p\<0.001, and proteinuria (D), r=0.27, p=0.008.](nihms373055f2){#F2}

![Illustrative kidney biopsies of two patients with membranous nephropathy. Urinary NGAL levels are indicated. Note the widened interstitial compartments, tubular flattening and tubular dilation in the more advanced case which expresses a ten fold higher level of NGAL. Mason trichrome stain. Bar=50μm.](nihms373055f3){#F3}

###### 

Relationship between clinical characteristics, GFR, proteinuria, NGAL-monomer and chronic histologic characteristics.

                                      Global Glomerulosclerosis                       Atherosclerosis   Interstitial Fibrosis                           Tubular Atrophy                                                                                                                     
  ----------------------------------- ----------------------------------------------- ----------------- ----------------------------------------------- ----------------- ------------------------------------------------ --------------- ------------------------------------------------ ---------------
  **Female (%)**                      34.4                                            26.9              35.7                                            24.6              32.4                                             22.6            33.8                                             19.4
  **Age (yrs)**                       48.1 (17.9)                                     52.4 (16.3)       46.0 (16.9)                                     55.9 (15.8)       49.6 (17.3)                                      56.2 (15.4)     48.8 (16.7)                                      58.1 (15.7)
  **HTN (%)**                         50[\*](#TFN1){ref-type="table-fn"}              74.6              52.4[\*](#TFN1){ref-type="table-fn"}            77.2              54.4[\*\*](#TFN2){ref-type="table-fn"}           93.5            55.9[\*\*](#TFN2){ref-type="table-fn"}           90.3
  **Diabetes (%)**                    12.5                                            16.4              7.1                                             21.1              7.4[\*\*](#TFN2){ref-type="table-fn"}            32.3            7.4[\*\*](#TFN2){ref-type="table-fn"}            32.3
  **PCreatinine (mg/dl)**             1.1 (0.5)[\*\*](#TFN2){ref-type="table-fn"}     1.9 (1.3)         1.2 (0.5)[\*\*](#TFN2){ref-type="table-fn"}     2.0 (1.4)         1.3 (0.6)[\*\*](#TFN2){ref-type="table-fn"}      2.5 (1.5)       1.3 (0.7)[\*\*](#TFN2){ref-type="table-fn"}      2.4 (1.6)
  **eGFR(ml/min)**                    81.7 (31.6)[\*\*](#TFN2){ref-type="table-fn"}   53.2 (29.1)       78.6 (31.5)[\*\*](#TFN2){ref-type="table-fn"}   50.1 (28.2)       73.4 (30.3)[\*\*](#TFN2){ref-type="table-fn"}    38.4 (23.5)     72.1 (31.5)[\*\*](#TFN2){ref-type="table-fn"}    41.3 (24.2)
  **Proteinuria (g/24hr)**            7.0 (6.3)                                       5.6 (5.8)         5.9 (6.0)                                       6.2 (6.0)         5.5 (5.0)                                        7.3 (7.8)       5.7 (5.8)                                        6.8 (6.5)
  **Mean uNGAL (μg/gr creatinine)**   53.4 (101.1)[\*](#TFN1){ref-type="table-fn"}    105.8 (232.0)     49.9 (80.1)                                     117.8 (252.3)     54.1 (111.0)[\*\*](#TFN2){ref-type="table-fn"}   167.1 (309.8)   54.1 (112.0)[\*\*](#TFN2){ref-type="table-fn"}   163.6 (305.2)

p\<.05 compared to present

p\<.01 compared to present.
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